IXICO plc - IXICO to Present AI Segmentation Research
("IXICO" or the "Company")
Further details of the presentation are as follows:
Title: Fully automatic AI segmentation of subcortical regions: comparison of ATLAS and deep-learning based approaches
Wednesday, 26th February, Group B: Human Studies at
Authors: Kirsi M Kinnunen1*, Jack Weatheritt1, Richard Joules1, Robin Wolz1,2
Changes in the volume of the caudate and putamen regions are used as biomarkers to track the development of Huntington's disease and monitor the potential effect of interventional treatments. Accurate volume calculations, obtained via segmentations, are therefore of utmost clinical importance. This poster compares and contrasts two AI approaches for anatomical segmentation - the first is an established atlas-based manifold learning technique, IXICO's proprietary LEAP technology; the second is a deep-learning model based on a 3D convolutional neural network (CNN).
Dr Robin Wolz, Senior Vice President, Science & Innovation at IXICO commented: "Huntington's Disease continues to be a focus for IXICO in its efforts to provide pioneering technologies to support the advancement of effective treatments for rare neurological diseases. Our research in imaging analytics will provide an insight into the best methods for monitoring both the progression of the disease as well as the potential effect of interventional treatments."
IXICO will be attending /presenting at upcoming conferences:
Neurodegenerative Drug Development Summit:
IXICO will be presenting at the conference.
The Wearable Technology Show:
ADPD Focus Meeting:
IXICO will be presenting and co-sponsoring the event.
For further information please contact:
| || |
+44 (0) 20 3763 7498
Alison Howie, Chief Product Officer
| || |
| || |
+44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
For more information, please visit https://chdifoundation.org/
This information is provided by RNS, the news service of the
Quick facts: IXICO PLC
Market Cap: £28.73 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE